Teleflex is like the Medtronic or Johnson & Johnson (medical device segment) of single-use medical devices, supplying a vast array of essential tools for critical care and surgery.

Alternatively, think of them as similar to Stryker or Boston Scientific, but with a broader portfolio of everyday, single-use medical tools and supplies for hospital procedures, from vascular access to urology.

• Vascular Access Products: Catheters and related systems for administering intravenous therapies, measuring blood pressure, and withdrawing blood samples.
• Interventional Products: Specialized catheters and devices used by interventional cardiologists, radiologists, and vascular surgeons for various procedures, including structural heart and peripheral interventions.
• Anesthesia Products: Airway and pain management products supporting critical care, emergency medicine, and surgical applications.
• Surgical Products: Metal and polymer ligation clips, fascial closure surgical systems, and other instruments for laparoscopic and other surgical procedures.
• Interventional Urology Products: The UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia.
• Respiratory Products: Devices for oxygen and aerosol therapies, spirometry, and ventilation management.
• Urology Products: Catheters, urine collectors, and accessories for bladder management and operative endourology.

Teleflex (TFX) sells primarily to other organizations and companies. Its major customers fall into the following categories:

• Hospitals and healthcare providers
• Medical device manufacturers
• Home care markets

Stuart Randle, Interim President and Chief Executive Officer

Stuart Randle was appointed Interim President and Chief Executive Officer of Teleflex on January 8, 2026. He has been a member of the Teleflex Board of Directors since 2009. Mr. Randle brings over 35 years of experience in the medical device industry. Prior to his current role, he served as Chief Executive Officer of Ivenix, Inc. for three years and as President and Chief Executive Officer of GI Dynamics, Inc. for ten years. His previous leadership experience also includes serving as Interim Chief Executive Officer of Optobionics Corporation from 2003 to 2004 and President and Chief Executive Officer of Act Medical from 1998 to 2001. He also held various senior management positions with Allegiance Healthcare Corporation and Baxter International Inc.

John R. Deren, Executive Vice President and Chief Financial Officer

John R. Deren is the Executive Vice President and Chief Financial Officer of Teleflex, a role he assumed on April 2, 2025. He joined Teleflex in 2013 and possesses over 30 years of experience in financial management and reporting. Mr. Deren's prior experience includes leadership positions at Rohm and Haas, Exelon Generation, and Trinseo. He started his career as a Certified Public Accountant (CPA) at PricewaterhouseCoopers.

Jay White, Corporate Vice President and President, Global Commercial

Jay White serves as Corporate Vice President and President, Global Commercial at Teleflex. He joined Teleflex in March 2005 as Director of Marketing, North America. He was promoted to President and General Manager of the Surgical business in January 2013, and subsequently became President and General Manager of the Vascular business in December 2013. In February 2017, he was named President, The Americas. Before joining Teleflex, Mr. White held senior leadership positions in sales and marketing at Covidien (now part of Medtronic plc) for five years. He holds a Bachelor of Science degree from the University of Missouri.

Daniel V. Logue, Corporate Vice President, General Counsel and Secretary

Daniel V. Logue is the Corporate Vice President, General Counsel and Secretary of Teleflex. He joined Teleflex in September 2015 as Vice President and Chief Compliance Officer. In February 2016, he assumed the role of Vice President, General Counsel, and Chief Compliance Officer, and was appointed Corporate Vice President in February 2017. Prior to joining Teleflex, Mr. Logue served as Vice President and Associate General Counsel for Allergan plc. He also held various legal leadership roles at Actavis plc and Pfizer Inc. He began his legal career in private practice at Drinker Biddle & Reath LLP. Mr. Logue holds a Juris Doctor from Temple University School of Law and a Bachelor of Arts from Villanova University.

Cameron Hicks, Corporate Vice President and Chief Human Resources Officer

Cameron Hicks is the Corporate Vice President and Chief Human Resources Officer at Teleflex. He joined Teleflex in April 2013, bringing over 23 years of experience in Human Resources and Organizational Development to his role. Prior to joining Teleflex, Mr. Hicks held various human resources leadership positions at other companies. He earned a Bachelor of Arts degree from the University of California, Santa Barbara.

1. Regulatory Hurdles and Product Recalls: Teleflex operates in a highly regulated industry, facing stringent requirements from bodies such as the U.S. Food and Drug Administration (FDA) and the European Union Medical Device Regulation (EU MDR). The process of obtaining and maintaining regulatory approvals can be lengthy, uncertain, and costly, including the re-registration of previously approved devices under new regulations. A significant risk also stems from product recalls due to manufacturing errors, which can lead to serious injuries or even death. For example, Teleflex has initiated Class I recalls for intra-aortic balloon catheter kits and peripheral catheter systems due to issues like overtwisted balloons or catheter separation, with reported injuries and deaths. Such recalls can result in significant legal and financial consequences, as well as damage to the company's reputation.
2. Intense Competition and Pricing Pressure: Teleflex faces significant competition from both large, diversified medical device companies (such as Medtronic, Boston Scientific, and Edwards Lifesciences) and specialized niche players across its various product segments. This competitive landscape can lead to pricing pressure, particularly in commoditized product lines, and challenges in maintaining or expanding market share. Competitors often leverage broad portfolios and distribution networks, putting pressure on Teleflex's market position in areas like vascular access and anesthesia.
3. Product-Specific Challenges and Demand Softness: Certain key product lines have experienced specific challenges. The UroLift System, an important interventional urology product, has faced headwinds due to changes in reimbursement policies. Additionally, Teleflex has seen softer demand for intra-aortic balloon pumps and catheters, as well as delays in OEM orders, which has led to trimmed revenue guidance. Overall, the company has observed declining long-term sales and constant currency revenue growth that has lagged the broader sector, suggesting underlying demand headwinds that could impact future profitability.

Addressable Markets for Teleflex Products and Services

• Interventional Cardiology Devices: The global interventional cardiology devices market was estimated at approximately USD 20.9 billion in 2025 and is projected to reach USD 46.8 billion by 2035. North America is a dominant region in this market, holding an estimated 44.91% share in 2025.
• Structural Heart Devices: The global structural heart devices market was valued at USD 12.3 billion in 2024 and is expected to reach USD 28.8 billion by 2034. Another report indicated a market size of USD 14.65 billion in 2025, projected to grow to USD 27.16 billion by 2034. North America held the largest revenue share in 2024, accounting for 52.5% of the global market. The U.S. structural heart devices market was valued at USD 3.8 billion in 2024.
• Anesthesia and Respiratory Devices: The global anesthesia and respiratory devices market was estimated at USD 56.12 billion in 2025 and is expected to reach USD 84.50 billion by 2032. North America is expected to hold a 42.3% share of this global market in 2025. Specifically, the U.S. anesthesia and respiratory devices market was valued at USD 9.24 billion in 2024 and is projected to reach approximately USD 17.44 billion by 2034.
• Surgical Instruments/Equipment: The global surgical equipment market was estimated at USD 20.75 billion in 2024 and is poised to grow to USD 48.14 billion by 2033. North America dominated the global market in 2024, holding a 38.2% share. The U.S. surgical instruments market is estimated to reach US$12.1 billion by 2031. The global minimally invasive surgical instruments market was valued at US$29.9 billion in 2023 and is projected to reach US$49.9 billion by 2029. The U.S. minimally invasive surgical instrument market was valued at USD 11.6 billion in 2025.
• Benign Prostatic Hyperplasia (BPH) Treatment Devices (including UroLift System): The global benign prostatic hyperplasia (BPH) treatment device market size was estimated at USD 1.67 billion in 2024 and is projected to reach USD 3.71 billion by 2033. Another report indicated the global market was valued at USD 4.9 billion in 2024, expected to reach USD 7.3 billion by 2030. North America dominated the BPH treatment device market with the largest revenue share of 33.87% in 2024.
• Respiratory Care Devices: The global respiratory care devices market size was valued at USD 25.33 billion in 2024 and is projected to grow to USD 39.24 billion by 2032. North America dominated this market with a 40.43% share in 2024, with the U.S. holding about 45% of the global market share.
• Urology Devices: The global urology devices market size was estimated at USD 36.8 billion in 2024 and is expected to grow to USD 73.5 billion in 2034. North America dominated the global urology devices market with the highest market share of 42.5% in 2024. The U.S. urology devices market was valued at USD 14.4 billion in 2024.

• Expansion of the Interventional Segment with strategic acquisitions and key products: The Interventional segment is projected to be a primary engine of growth, with expectations for a high-single-digit expansion rate. A significant contributor to this growth is the acquired BIOTRONIK Vascular Intervention business, which is anticipated to achieve constant currency revenue growth of 6% or more starting in 2026. This acquisition enhances Teleflex's offerings in the interventional cardiology and peripheral intervention markets, including a broad suite of devices such as drug-coated balloons and stents. Additionally, the MANTA Vascular Closure Device is expected to contribute to revenue growth, particularly in large-bore closure procedures like TAVR, leveraging its proven efficacy and growing adoption in international markets.
• Increased Investment in Research and Development (R&D) and Product Innovation: Teleflex plans to increase its R&D spending for its continuing operations to approximately 8% of sales, a notable increase from its historical 5% company-wide allocation. This elevated investment is strategically directed towards fostering procedural simplicity, integrating AI augmentation, and launching new products within its core Vascular Access, Interventional, and Surgical segments. This focus on innovation aims to address unmet clinical needs and differentiate its product portfolio, thereby stimulating demand and revenue growth.
• Targeted Geographic Expansion and Market Penetration: The company is focused on expanding its global footprint and increasing market penetration, particularly in emerging markets and key regions such as EMEA (Europe, Middle East, and Africa) and Asia. This strategy involves localized product portfolios and leveraging targeted sales channels and distributor partnerships to capitalize on growth opportunities in these regions for its Vascular Access, Interventional, and Surgical product lines. For instance, analysts anticipate significant year-over-year growth in geographic revenues for both EMEA and Asia.
• Realization of Operational Efficiencies and Margin Expansion through Restructuring: Teleflex has initiated a multi-year restructuring plan designed to achieve approximately $50 million in annual pre-tax savings by mid-2028. These cost structure initiatives, coupled with a favorable sales mix towards higher-margin products, are projected to enhance the adjusted operating margin. While primarily impacting profitability, improved efficiencies and margin expansion can indirectly support revenue growth by allowing for more competitive pricing strategies or by freeing up capital for further investments in product development and market expansion.

Share Repurchases

• Teleflex authorized a $500 million share repurchase program in July 2024, initiating a $200 million accelerated share repurchase in August 2024.
• The company intended to commence an additional $300 million accelerated share repurchase in February 2025 under the existing $500 million authorization.
• In December 2025, Teleflex authorized a new $1 billion share repurchase program, primarily to be funded by proceeds from upcoming business divestitures.

Outbound Investments

• Teleflex acquired Palette Life Sciences AB in October 2023, an acquisition that contributed to better-than-expected performance, with 2024 revenue guidance for Palette raised to $70-$72 million.
• In July 2025, Teleflex completed the acquisition of substantially all of BIOTRONIK's Vascular Intervention business for €760 million (approximately $826 million). This acquisition expanded Teleflex's interventional portfolio with devices such as drug-coated balloons, stents, and balloon catheters, and was expected to generate approximately €177 million in revenue in the second half of 2025.

Capital Expenditures

• For the 2023 Footprint realignment plan, Teleflex expected to incur $2 million to $3 million in aggregate capital expenditures, mostly in 2024, focusing on relocating manufacturing operations to lower-cost locations.
• By June 2024, the company incurred $1.1 million in pre-tax restructuring related charges under the 2024 Footprint realignment plan, with the majority of associated capital expenditures anticipated by the end of 2025.
• Capital expenditures for the third quarter of 2025 were reported as $29.9 million.